The BRAFV600E mutation maintains the aggressiveness of papillary thyroid cancers requiring downregulation of primary cilia

Mol Cell Endocrinol. 2024 Feb 1:581:112113. doi: 10.1016/j.mce.2023.112113. Epub 2023 Nov 19.

Abstract

Although disorders of primary cilia (PCs) were first reported in human papillary thyroid cancer (PTC) tissues in 1987, their precise role in PTC remains unclear. PCs sense the thyroid follicle colloid environment and act as a cell signaling hub. The present study investigated whether PCs are needed for BRAFV600E-driven PTC. We assessed whether BRAFV600E protein expression correlates with papillary histological architecture and clinicopathological features of PTC. We found that expression of ciliary intraflagellar transport 88 (IFT88) and PC formation were reduced in BRAFV600E-driven PTCs and that loss of cilia may be associated with lymph node metastasis. In PTC cells, the BRAFV600E mutation maintained the aggressiveness of PTC, which was partially related to loss of PCs. Our work confirms that BRAFV600E mutation-driven PC downregulation contributes to maintaining the aggressiveness of PTCs and that manipulating PC can potentially reduce the adverse incidence of PTC in a range of conditions.

Keywords: Aggressiveness; BRAF(V600E); Papillary thyroid cancers; Primary cilium.

MeSH terms

  • Carcinoma, Papillary* / genetics
  • Carcinoma, Papillary* / pathology
  • Cilia / metabolism
  • Down-Regulation / genetics
  • Humans
  • Mutation / genetics
  • Proto-Oncogene Proteins B-raf / genetics
  • Proto-Oncogene Proteins B-raf / metabolism
  • Thyroid Cancer, Papillary / genetics
  • Thyroid Neoplasms* / pathology

Substances

  • Proto-Oncogene Proteins B-raf
  • BRAF protein, human